The DOI matches its Crossref record.
Protective Effect of WC3 Vaccine Against Rotavirus Diarrhea in Infants During a Predominantly Serotype 1 Rotavirus Season
Open accessAbstract
We used a double-blind, placebo-controlled trial to study the efficacy of WC3 rotavirus vaccine administered to 104 infants (ages, three to 12 months) before the rotavirus season. Forty-nine infants received vaccine; 55 received placebo. Rotavirus disease during this season was predominantly caused by a serotype 1 strain. In placebo recipients there were 14 cases of rotavirus diarrhea (attack rate, 25%); 11 were moderate to severe (attack rate, 20%). Vaccinees experienced only three cases of rotavirus disease (attack rate, 6.1%), all mild. When all cases (whether associated with rotavirus or not) of clinically significant diarrhea (CSD) were evaluated, WC3 vaccine provided statistically significant (P less than .01) protection against the total number of episodes of CSD and reduced the number of days of CSD-associated diarrhea, vomiting, fever, or illness. Seventy-one percent of the WC3-vaccinated infants had serum antibody responses to the vaccine. The 14 placebo recipients who experienced natural disease predominantly had antibody responses to serotype 1. Sera taken after the rotavirus season revealed a nearly identical rate (40%) of natural rotavirus infection in the vaccinated and placebo groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Matthijnssens, J., Ciarlet, M., McDonald, S. M., Attoui, H., Bányai, K., Brister, J. R., Buesa, J., Esona, M. D., Estes, M. K., Gentsch, J. R., et al. (2011) · Archives of Virology · doi:10.1007/s00705-011-1006-z · Cited by 999
Rotavirus gene structure and function.
Estes, M. K., & Cohen, J. (1989) · Microbiological Reviews · doi:10.1128/mmbr.53.4.410-449.1989 · Cited by 885
Zaman, K., Anh, D. D., Victor, J. C., Shin, S., Yunus, M., Dallas, M. J., Podder, G., Thiem, V. D., Mai, L. T. P., Luby, S. P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60755-6 · Cited by 824
Ruuska, T., & Vesikari, T. (1990) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549009027046 · Cited by 714
Armah, G. E., Sow, S. O., Breiman, R. F., Dallas, M. J., Tapia, M. D., Feikin, D. R., Binka, F. N., Steele, A. D., Laserson, K. F., Ansah, N. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60889-6 · Cited by 654
Rotavirus vaccines: current prospects and future challenges
Glass, R. I., Parashar, U. D., Bresee, J. S., Turcios, R., Fischer, T. K., Widdowson, M.-A., Jiang, B., & Gentsch, J. R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68815-6 · Cited by 482
Rotavirus Vaccines: an Overview
Dennehy, P. H. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-07 · Cited by 399
Kotloff, K. L., Blackwelder, W. C., Nasrin, D., Nataro, J. P., Farag, T. H., van Eijk, A., Adegbola, R. A., Alonso, P. L., Breiman, R. F., Golam Faruque, A. S., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis753 · Cited by 373
Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis.
Yolken, R. H., Peterson, J. A., Vonderfecht, S. L., Fouts, E. T., Midthun, K., & Newburg, D. S. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116078 · Cited by 345
Joensuu, J., Koskenniemi, E., Pang, X.-L., & Vesikari, T. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05118-0 · Cited by 312
Dennehy, P. H. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.102 · Cited by 281
Immunity and correlates of protection for rotavirus vaccines
Franco, M. A., Angel, J., & Greenberg, H. B. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.12.048 · Cited by 268
Parashar, U. D., Bresee, J. S., Gentsch, J. R., & Glass, R. I. (1998) · Emerging Infectious Diseases · doi:10.3201/eid0404.980406 · Cited by 256
Metadata
- Authors
- Clark, H. F., Horian, F. E., Bell, L. M., Modesto, K., Gouvea, V., & Plotkin, S. A.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1988-09-01
- Volume
- 158
- Issue
- 3
- Pages
- 570-587
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2151100928
- Cited by
- 242
- References
- 0
- FWCI
- 19.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.